Pse-T2-Based Short Peptides with Broad-Spectrum Antimicrobial Activity, Stability, and Safety Combat MDR

Abstract read

In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hee Kyoung KangDepartment of Biomedical Science and Institute for Peptide Drugs (IPD), Chosun University, Gwangju 61452, Republic of Korea.

Yoonkyung ParkDepartment of Biomedical Science and Institute for Peptide Drugs (IPD), Chosun University, Gwangju 61452, Republic of Korea.ORCID 0000-0002-8717-3080

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infections caused by MDR pathogens are on the rise worldwide, and relying on conventional antibiotics can be life-threatening for patients. To address this issue, we used a functional truncated peptide, Pse-T2-C12, which exhibited excellent antibacterial, antibiofilm, and antipersister activities, along with a rapid killing rate against all tested pathogens. Pse-T2-C12 kills bacterial cells via pore formation, permeabilization, and disruption of bacterial membranes. Pse-T2-C12 did not induce resistance development, remained stable over pH, temperature, and serum conditions, and showed no detectable toxicity

Indexed as

Anti-Bacterial AgentsAntimicrobial PeptidesDrug Resistance, Multiple, BacterialStaphylococcal InfectionsStaphylococcus aureusAnimalsBiofilmsDisease Models, AnimalFemaleHumansMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsAntimicrobial PeptidesAntibiotic resistanceAntimicrobial peptideSepsisSequence predictionStaphylococcus aureus

Identifiers

PMID40674463

DOI10.1021/acsinfecdis.4c01034

PMCPMC12706780

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.